Bacteroides Vulgatus

This is one of the most abundant bacteria in the human colon, and it behaves differently depending on who you are. In people with coronary artery disease it runs low. In people with active ulcerative colitis, certain strains of it run high and secrete enzymes that chew on the gut lining. Same organism, opposite story.

That duality is the reason to read this result carefully rather than as a score. There is no standardized clinical cutpoint for it, no guideline that says test it, and no target number to hit. What it gives you is a baseline in one of your gut's largest bacterial populations, and a way to watch it move.

What This Test Actually Measures

B. vulgatus (Bacteroides vulgatus, recently reclassified by taxonomists as Phocaeicola vulgatus) is a bacterium that lives in your colon and grows without oxygen. The lab finds it in stool by copying a stretch of its DNA specific enough to name the species, then reporting how much is there.

What it does for a living is ferment complex carbohydrates. It breaks down the dietary fibers and plant sugars your own enzymes cannot touch. Along the way it shapes the chemistry of your gut: it alters the mix of bile acids your liver sends down, it influences short-chain fatty acids, and it produces small signaling molecules. One of those, 4-hydroxyphenylacetic acid, has been studied in mice with chemically induced colitis, where it eased gut inflammation and depression-like behavior. That work has not been repeated in people.

One more thing separates this from a standard stool test. Clinical stool PCR panels hunt for pathogens: Clostridioides difficile, Salmonella, norovirus. This organism is a normal resident of the gut, not a pathogen. It lives in nearly everyone, so a positive result is expected. The question is how much, relative to your own prior results and to the rest of your gut community.

Ulcerative Colitis and the Protease Problem

The strongest mechanistic human evidence here comes from ulcerative colitis, and it is the clearest example of why more is not always better. In a study of ulcerative colitis stool that paired DNA sequencing with protein and chemical measurements, strains of this organism that pump out large amounts of serine proteases were linked to worse disease. Serine proteases are enzymes that cut other proteins apart. These ones directly disrupt the lining of the intestine, and their abundance tracked with how severe the disease looked on endoscopy and under the microscope.

This is strain-level, not species-level. Two people can carry the same species at the same abundance and have entirely different protease output, because one carries a benign strain and the other does not. A PCR result reporting species abundance cannot tell those two people apart. That limitation is real and worth holding onto when you read your own number.

A separate finding in ulcerative colitis extends this to surgery. In a cohort of 21 people who underwent colectomy with ileal pouch-anal anastomosis, higher preoperative stool levels of this organism, alongside Ruminococcus gnavus, marked a higher risk of pouchitis in the first year after the operation. That is the closest thing in this literature to a forward-looking clinical signal, and it comes from a small study.

Crohn's Disease Runs the Other Way

In Crohn's disease, the direction flips. Fecal profiling found this organism, along with butyrate-producing bacteria, reduced roughly five to tenfold compared with healthy controls. Depletion, not overgrowth, is what the disturbed community looks like there.

So within inflammatory bowel disease itself, the two major subtypes point opposite directions. A high number and a low number can both mean trouble, depending on which disease you have. This is the first place where a naive reading of the result breaks down.

Why the Contradictions Are Not Actually Contradictions

Here is the resolution. It works as an ecological indicator rather than a good-number, bad-number marker, and what it indicates depends on context: which strain you carry, what else is living alongside it, and what your immune system is already doing. The same species can supply a useful compound in one gut and secrete a barrier-damaging enzyme in another. Nothing about that is paradoxical once you stop treating abundance as a verdict.

Practically, this means a single value in isolation tells you almost nothing. Read it against the rest of your microbiome panel, against your symptoms, and against your own previous results. A shift in your own numbers over time is far more interpretable than where you fall in a reference population.

Coronary Artery Disease

People with coronary artery disease carry less of this organism, and less of its close relative Bacteroides dorei, than people without it. That comparison is the human evidence, and it was measured at a single point in time.

The mechanism has only been tested directly in animals. Feeding the live bacteria to mice cut the amount of lipopolysaccharide their gut community produced and reduced arterial plaque. Lipopolysaccharide is a fragment of bacterial cell wall that drives inflammation when it crosses into the bloodstream. That is a clean experiment, but it is a mouse experiment. Nothing here shows that raising your own level would protect your arteries.

If you are already tracking cardiovascular risk, this is a complement to the markers that actually predict events, not a substitute for them. ApoB, Lp(a), and hs-CRP have decades of outcome data behind them. This has one cross-sectional human comparison and a mouse model.

Type 1 Diabetes and Early Autoimmunity

In children followed from infancy, the gut bacterial community already looks different before islet autoantibodies appear. Islet autoimmunity is the first measurable step toward type 1 diabetes, so the timing is interesting: the microbial shift comes first. What the research does not give you is a consistent direction for this species. Studies in the same Finnish at-risk cohorts have reported it and its close relative Bacteroides dorei running both higher and lower in the children who went on to seroconvert.

And as a standalone predictor, it is weak. In a pediatric cohort, this species alone barely separated children with type 1 diabetes from those without, with area-under-the-curve values ranging from 0.29 to 0.69, where 0.5 is a coin flip. Combined with three other species, the same panel reached 0.83. That gap is the lesson: this organism is a panel component, not a test.

Colorectal Cancer

The colorectal cancer evidence is split, and you should know that before you read your result. In one structural comparison of gut microbiota in 102 people, healthy volunteers carried higher counts than people diagnosed with colorectal cancer. A later meta-analysis pooling case-control studies found the opposite, reporting this organism enriched in colorectal cancer across multiple regions.

A Danish nationwide cohort adds a different angle, and it is about blood rather than stool. Among 11,124 episodes in which a gut anaerobe was found in the bloodstream, Phocaeicola vulgatus or dorei was followed by a colorectal cancer diagnosis within a year in 5.5% of cases. A gut anaerobe in the blood is a recognized flag for an undiagnosed colon lesion. It has nothing to do with normal stool colonization.

Nothing in this literature supports using a stool result as a colorectal cancer screen. Colonoscopy and fecal immunochemical testing are the screens with outcome evidence behind them. If you are due, get one of those.

Metabolic, Bone, and Hormonal Associations

Several other human associations exist, all cross-sectional, all measured at a single point in time. In polycystic ovary syndrome, women carried higher levels of this species alongside altered bile acid handling. The rest of that story is mouse work: transferring the bacterium into mice produced insulin resistance, suppressed intestinal interleukin-22 signaling, and disturbed ovarian function. In peri- and postmenopausal women, abundance correlated inversely with bone mineral density. Valeric acid is the proposed go-between there; it is a short-chain fatty acid that restrains the cells which break bone down. In type 2 diabetes, people carrying this species in stool also had higher blood interleukin-6, one of the body's main inflammation signals.

Read these as leads, not findings you can act on. None establish that changing your level changes the outcome. Cross-sectional design cannot separate cause from consequence, and BMI and age both independently reshape microbial composition, which means confounding is hard to rule out.

Why One Reading Is Not Enough

Start with the number that should govern how you read every other number here. In quantitative daily profiling of adults, 78% of gut microbial genera fluctuated by up to a hundredfold between consecutive days. Stool moisture, transit time, and what you ate this week all drive that. A single sample caught on a bad day can land far from your true typical level.

The reassuring counterpoint is that rank order holds up better than absolute counts. Across long-running stool sequencing studies, species-level reliability over months to two years sits around 0.75 on a scale where 1.0 is perfect agreement. Your position relative to other people is fairly stable even when your raw number bounces. So a single sample places you reasonably well in a population, and a series of samples tells you something about you.

Get a baseline. If you are changing diet, starting or stopping a probiotic, or recovering from antibiotics, retest at 3 to 6 months to see whether anything actually moved. Then at least annually. Two samples a few weeks apart before you conclude anything from an unexpected result is reasonable given the day-to-day swing.

What to Do With an Out-of-Pattern Result

An unexpected number here is a prompt to look wider, not to treat the bacterium. Nobody has established a threshold that warrants intervention, and no treatment has been shown to improve an outcome by targeting this species.

If you have gut symptoms, the first move is to get objective inflammation data: fecal calprotectin plus hs-CRP. Calprotectin is a protein that immune cells dump into the bowel when they migrate into the gut wall, so it reads inflammation in the intestine itself. hs-CRP reads low-grade inflammation across the whole body. Together they tell you whether real mucosal inflammation is present, which is the question that actually changes management. A microbiome-based multi-species panel has outperformed calprotectin for separating inflammatory bowel disease from controls in research settings, but calprotectin is what clinicians act on today.

If you have no symptoms, look at the pattern rather than the single species. Depleted butyrate producers such as Faecalibacterium prausnitzii alongside a shifted Bacteroides population is a more meaningful picture than any one value. Pair that with the markers that do carry outcome data: ApoB and Lp(a) for cardiovascular risk, HbA1c and fasting insulin for metabolic risk, and age-appropriate colorectal cancer screening.

Two patterns do warrant a clinician. Blood in the stool, unexplained weight loss, or persistent diarrhea need a gastroenterologist and a real workup regardless of what any microbiome panel says. And if you are facing colectomy with pouch construction for ulcerative colitis, the pouchitis data are worth raising with your surgical team, with the caveat that they come from a 21-person study.

When Results Can Be Misleading

Four things can throw this result off enough to change how you read it.

• Stool moisture and transit: looser stool dilutes bacterial density and firmer stool concentrates it. This is the single largest source of noise in absolute stool quantification, and it can move a result substantially without anything biological changing.
• Recent antibiotics: systemic antibiotics reshape the community for weeks to months. In infants, antibiotic exposure raised the relative abundance of this species by about 1.7 percentage points while depleting Bacteroides fragilis. A sample taken soon after a course reflects the drug, not your baseline.
• DNA extraction method: the extraction kit a lab uses is the largest single technical influence on which microbes get recovered. Results from two different labs are not directly comparable, so stick with one lab for serial testing.
• Species look-alikes: this organism's DNA is very close to that of its relatives, particularly Bacteroides dorei. Common sequencing methods can struggle to separate them, and much of the cardiovascular research treats the two together.

How Mature Is This Marker

This is a research marker. There are no standardized clinical cutpoints, no guideline recommends it, and no study has shown that testing asymptomatic adults changes management or improves outcomes. As a solo diagnostic it does not perform. In the one setting where stool PCR for Bacteroides has been checked against an actual diagnosis, fatty liver disease, it caught about 67 out of 100 cases and correctly cleared about 83 out of 100 people without it. That measurement was made across the broader Bacteroides group rather than this single species, and either way it is not enough to rule anything in or out.

That is an argument for interpreting it modestly, not for skipping it. Baselines only get valuable with time, and the science here is moving. Having your own series from a consistent lab means that when strain-level testing and validated thresholds arrive, you will have history to read them against. Just do not let an abnormal value here pull you toward a treatment that no evidence supports.